1. Pink Sheet
  2. >>Legislation

Shanghai Seizes Cell Samples As China Tightens Biosecurity Enforcement

First Action Since 15 April Law Enactment

 
• By Brian Yang

Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized. 

China tightens biosecurity law enforcement
CHINA TIGHTENS BIOSECURITY LAW ENFORCEMENT IN LATEST ACTION • Source: Alamy

Shanghai Customs authorities announced on 9 May they had intercepted over 200 human cell samples imported from overseas that had been disguised as other liquid cultures.

The importer, an unnamed biotech firm in Shanghai, was found to “hidden 247 reagents of human cells” and to “have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 
• By Bridget Silverman

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 
• By Bridget Silverman

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 
• By Francesca Bruce

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.